|View printer-friendly version|
|Emergent BioSolutions to Participate in June 2010 Investor Conferences|
ROCKVILLE, Md., Jun 01, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be participating in the following investor conferences during June 2010.
Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under "Investors".
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.